RIGL Key Statistics, Chart & Performance
The current stock price of RIGL is 41.83 USD. In the past month the price decreased by -11.4%. In the past year, price increased by 140.68%.
RIGL Latest News, Press Relases and Analysis
RIGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About RIGL
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Company Info
RIGEL PHARMACEUTICALS INC
611 Gateway Boulevard, Suite 900
South San Francisco CALIFORNIA 94080 US
CEO: Raul R. Rodriguez
Employees: 163
Phone: 16506241100
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What does RIGEL PHARMACEUTICALS INC do?
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
What is the current price of RIGL stock?
The current stock price of RIGL is 41.83 USD. The price decreased by -2.33% in the last trading session.
What is the dividend status of RIGEL PHARMACEUTICALS INC?
RIGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RIGL stock?
RIGL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Is RIGEL PHARMACEUTICALS INC (RIGL) expected to grow?
The Revenue of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 67.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a market capitalization of 759.21M USD. This makes RIGL a Small Cap stock.
Can you provide the ownership details for RIGL stock?
You can find the ownership structure of RIGEL PHARMACEUTICALS INC (RIGL) on the Ownership tab.
RIGL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RIGL. When comparing the yearly performance of all stocks, RIGL is one of the better performing stocks in the market, outperforming 97.46% of all stocks.
RIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to RIGL. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
RIGL Financial Highlights
Over the last trailing twelve months RIGL reported a non-GAAP Earnings per Share(EPS) of 6.17. The EPS increased by 4307.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 40.17% | ||
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| Debt/Equity | 0.25 |
RIGL Forecast & Estimates
12 analysts have analysed RIGL and the average price target is 46.24 USD. This implies a price increase of 10.54% is expected in the next year compared to the current price of 41.83.
For the next year, analysts expect an EPS growth of 611.29% and a revenue growth 67.77% for RIGL